

Appendixes

Appendix A: Cervical cancer—symptoms, detection and treatment

Cervical cancer affects the cells of the cervix, which is the lower part of the womb or uterus as it joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where normal cells change, begin to multiply out of control, and form a growth or tumour. The cancer may arise from the squamous cells at the transformation zone where the squamous cells on the outside of the cervix join the columnar cells in the lining of the cervical canal (squamous cell carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over two-thirds of cervical cancers are squamous cell carcinomas, which are most easily detected on the Pap smear, and about 20% are adenocarcinomas. If not detected early, the tumour can invade local tissue and spread (metastasise) to other parts of the body. The main symptoms of cervical cancer are unusual bleeding from the vagina, and very rarely an unusual vaginal discharge. However, these symptoms are quite common and may not be due to cancer.

A cervical cancer may take 10 or more years to develop, but before this the cells may show pre-cancerous changes. These early changes can be detected by a Pap smear (which is described in more detail below), and with early treatment of these abnormalities, cervical cancer can be prevented. The most recent classification of these pre-cancerous lesions has two levels of severity, low-grade epithelial abnormalities (LGEA) and high-grade epithelial abnormalities (HGEA). An earlier classification described various grades of cervical intra-epithelial neoplasia (CIN). Low-grade abnormalities include minor changes in squamous cells and CIN 1, and high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma-in-situ, adenocarcinoma in situ and invasive carcinoma (squamous or adenocarcinoma).

The Pap smear is the most common way to detect pre-cancerous changes which rarely cause any symptoms. The test involves a doctor or nurse practitioner inserting a speculum into the vagina and gently scraping the surface of the cervix. This process collects cells that are transferred onto a slide or into a special liquid, which is then sent to a pathology laboratory for assessment. Pap smears are provided by general practitioners, gynaecologists, women's health nurses and, in some locations, Indigenous women's health workers.

When a Pap smear shows an abnormality, the woman may be advised to have a repeat smear if the abnormality is low-grade or she may be advised to have a colposcopy. With colposcopy, a doctor is able to look directly at the cervix under magnification using an instrument called a colposcope. Using a special stain the doctor can highlight any suspicious area, which may be pre-cancerous or cancerous. The doctor will then take a tissue sample (a biopsy) of the suspicious area for further examination by the pathologist.

Pre-cancerous changes can be easily and effectively treated to prevent the progression to cervical cancer. The type of treatment depends on whether the change observed is low or high grade, the woman's age and general health, whether she wants to have children, and her preferences.

There is a range of treatments for pre-cancerous changes, including laser treatment, loop excision (LLETZ), cryosurgery (cold coagulation), electrodiathermy, or cone biopsy (either by laser or by scalpel). In a small number of instances, a hysterectomy may be necessary.

For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells are detected on the surface of the cervix only, it may be treated by a cone biopsy. If it has invaded more deeply into the cervix, a hysterectomy is generally performed. In advanced cases, a radical hysterectomy is needed to remove the cervix and uterus along with a margin of tissue around the cervix and lymph nodes from the pelvis. Radiotherapy is sometimes used as well as surgery, and for more advanced cases it may be used on its own.

Appendix B: Data sources and limitations

All data used in this report are based on calendar years. Data are derived from multiple sources and are summarised below.

Table B1: Cervical cancer screening indicators data sources

Indicator	Description	Data source
1	Participation rate for cervical cancer screening	National Cervical Screening Program
2	Early re-screening	National Cervical Screening Program
3	Low-grade abnormality detection	National Cervical Screening Program
4	High-grade abnormality detection	National Cervical Screening Program
5.1	Incidence of micro-invasive cervical cancer National Cancer Statistics Clearing House (ICD10 C53)	National Cancer Statistics Clearing House
5.2	Incidence of squamous, adenocarcinoma, adenosquamous and other cervical cancer (ICD10 C53)	National Cancer Statistics Clearing House
5.3	Incidence by location (ICD10 C53)	National Cancer Statistics Clearing House
6.1	Mortality from cervical cancer (ICD9 180 for data up to and including 1996; ICD10 C53 for data from 1997 onwards)	AIHW Mortality Database
6.2	Mortality by location	AIHW Mortality Database
6.3	Mortality by Indigenous status	AIHW Mortality Database

Population data

The Australian Bureau of Statistics estimated resident female population has been used to calculate incidence and mortality rates. Participation rates were calculated using the average of the 2001 and 2002 estimated resident female population (see Appendix D for tables). There may be some variation in published participation rates because national rates use estimated resident population data in the denominator whereas local data analysis may use Census counts. The denominator population used to calculate cervical screening participation rates has been adjusted by the estimated proportion of women who have had a hysterectomy by age. These data were derived from the 2001 National Health Survey, and are tabulated in Appendix D.

The age-standardised rates in this publication are calculated using the total estimated 2001 mid-year Australian resident population. Where appropriate, rates are also standardised to the WHO World Standard Population for international comparison. Both the Australian Standard Population and the WHO World Standard Population are in Appendix D.

Indigenous mortality data

Due to the difficulties of Indigenous identification, mortality data used in Indicator 10 are based on deaths in Queensland (for 1998, 1999, 2000, 20001 and 2002), Western Australia, South Australia and the Northern Territory only.

Other data limitations

- Hysterectomy fractions are calculated from national data derived from the ABS National Health Survey using aggregate data that does not necessarily reflect variation at the state or territory level. In this report, data from the 2001 National Health Survey have been used.
- Participation rates will be underestimates to the extent that a small percentage of women choose to opt-off local registers and have been excluded from the statistics in this report.
- The participation numbers for states and territories other than Victoria and the Australian Capital Territory and the Australian totals may be overestimated because of double counting of some women in registers. This may be the result of difficulty in identifying state or territory of residence for women in border areas and the inclusion in registers of women resident overseas.
- Participation rates published by state and territory programs may differ from those in this publication because of variation in denominators used.
- Rates for all ages in incidence and mortality sections are based on data for women aged 15 years and over. This may have the impact of making incidence and mortality estimates for the same year incompatible between publications.

Appendix C: Methods

This appendix describes the methods used to calculate the estimates presented in the tables in the body of this publication.

Crude rates

A crude rate is defined as the number of events over a specified period of time (e.g. a year) divided by the total population. For example, a crude cancer incidence rate is defined as the number of new cases of cancer in a specified period of time divided by the population at risk. Crude death rates and cancer incidence rates are expressed in this report as rates per 100,000 population. Crude participation rate is expressed as a percentage.

Age-specific rates

Age-specific rates are calculated by dividing the number of cases occurring in each specified age group by the corresponding population in the same age group expressed as a percentage or a rate per 1,000 or 100,000 population. This rate may be calculated for particular age and sex groupings, e.g.

$$\begin{aligned} \text{Age-specific} \\ \text{cervical cancer} \\ \text{incidence rate in} \\ \text{females aged 50-54} \\ \text{in the year 2000} &= \frac{\text{New cases aged 50 – 54 years (year 2001)}}{2001 \text{ female population aged 50 – 54 years}} \times 100,000 \\ &= \frac{78}{648,237} \times 100,000 \\ &= 12.0 \text{ per } 100,000 \end{aligned}$$

Age-standardised rates (AS rate)

Rates are adjusted for age to facilitate comparisons between populations that have different age structures, e.g. between youthful and ageing communities. There are two different methods commonly used to adjust for age. In this publication we use direct standardisation in which age-specific rates are multiplied by a constant population (the Australian 2001 Standard Population unless otherwise specified). This effectively removes the influence of age structure on the summary rate that is described as the age-standardised rate. The method may be used for the calculation of participation, incidence and mortality rates. The method used for this calculation comprises three steps:

Step 1: Calculate the age-specific rate (as shown above) for each age group.

Step 2: Calculate the expected number of cases in each 5-year age group by multiplying the age-specific rates by the corresponding standard population and dividing by 100,000, giving the expected number of cases.

Step 3: Sum the expected number of cases in each age group to give the age-standardised rate. Divide this sum by the total of the standard population and multiply by 100,000.

Confidence intervals

Population numbers for incidence, mortality and screening have a natural level of variability for a single year above and below what might be expected in the mean over many years. The percentage variability is small for large population numbers but high for small numbers such as mortality in a young age group. One measure of the likely difference is the standard error, which indicates the extent to which a population number might have varied by chance in only one year of data.

In the 95% confidence interval there are about nineteen chances in twenty that the difference will be less than two standard errors.

The 95% confidence intervals in this report were calculated using a method for obtaining approximate confidence intervals for a weighted sum of Poisson parameters developed by Dobson et al. (1991).

Appendix D: Population data

Table D1: Australian Standard Population^(a) and WHO World Standard Population^(b)

Age group	World Standard Population	Australian 2001 Standard Population
0–4	8.86	1,282,357
5–9	8.69	1,351,664
10–14	8.60	1,353,177
15–19	8.47	1,352,745
20–24	8.22	1,302,412
25–29	7.93	1,407,081
30–34	7.61	1,466,615
35–39	7.15	1,492,204
40–44	6.59	1,479,257
45–49	6.04	1,358,594
50–54	5.37	1,300,777
55–59	4.55	1,008,799
60–64	3.72	822,024
65–69	2.96	682,513
70–74	2.21	638,380
75–79	1.52	519,356
80–84	0.91	330,050
85+	0.63	265,235
Total	100.03	19,413,240

Sources

(a) ABS (2002).

(b) Ahmad et al. 2002.

Table D2: Hysterectomy fractions for women aged 15–80+ years, Australia, 2001

Age group	% of women who have not had a hysterectomy
18–19	100.0
20–24	100.0
25–29	100.0
30–34	98.9
35–39	95.6
40–44	90.6
45–49	82.5
50–54	76.5
55–59	66.2
60–64	68.9
65–69	66.8
70–74	68.1
75–79	67.9
80+	69.0
Total	85.5

Source: ABS 2001 National Health Survey.

Table D3: Estimated resident female population, states and territories, June 2000

Age group	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Australia
0–4	212,248	150,048	119,160	61,978	45,470	15,236	10,327	8,521	623,100
5–9	220,812	159,285	126,800	65,717	48,675	16,633	10,858	8,396	657,321
10–14	217,827	157,685	124,667	67,662	49,127	16,792	11,001	7,584	652,475
15–19	214,103	157,159	126,223	66,450	49,724	16,702	11,844	7,147	649,402
20–24	211,077	158,650	121,765	63,301	46,456	14,071	12,778	7,714	635,881
25–29	247,422	184,117	135,753	69,930	51,486	15,541	13,323	9,359	727,009
30–34	240,000	185,289	131,615	70,453	53,291	16,169	12,582	8,816	718,323
35–39	255,711	188,110	140,417	74,799	57,901	18,242	12,852	8,251	756,421
40–44	244,599	180,407	134,766	73,321	57,577	18,175	12,722	7,226	728,900
45–49	224,723	166,671	124,670	68,226	54,103	16,897	12,337	6,405	674,128
50–54	207,920	154,790	116,441	60,200	51,550	15,772	11,315	5,088	623,134
55–59	161,449	117,249	88,394	44,223	39,070	12,350	7,449	3,255	473,483
60–64	137,200	100,964	70,601	36,564	33,626	10,633	5,336	1,900	396,853
65–69	121,266	89,014	59,494	30,663	30,036	9,263	4,102	1,235	345,081
70–74	118,405	86,798	56,363	28,027	30,669	8,777	3,742	853	333,643
75–79	102,665	74,696	48,012	23,354	27,472	7,758	3,225	560	287,744
80–84	68,156	48,613	32,106	15,366	18,064	5,345	1,975	369	190,000
85+	61,529	46,288	28,770	15,009	16,988	4,673	1,607	286	175,151
Total	3,267,112	2,405,833	1,786,017	935,243	761,285	239,029	159,375	92,965	9,648,049

Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).

Table D4: Estimated resident female population, states and territories, June 2001

Age group	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Australia
0–4	213,086	150,321	120,456	61,905	44,962	15,150	10,272	8,594	624,858
5–9	220,990	159,060	127,970	65,655	48,495	16,360	10,824	8,379	657,874
10–14	220,821	159,577	127,233	68,044	48,716	16,771	11,073	7,723	660,094
15–19	218,197	160,653	128,582	68,177	50,536	16,636	12,060	7,173	662,077
20–24	212,719	160,769	123,091	63,913	46,344	13,999	13,122	7,616	641,636
25–29	241,462	178,268	132,503	67,908	49,170	14,721	13,030	9,029	706,171
30–34	248,361	191,148	136,310	72,069	53,575	16,257	12,838	9,047	739,696
35–39	253,112	187,977	139,855	74,293	56,832	17,524	12,849	8,204	750,770
40–44	250,299	184,241	138,896	74,398	58,196	18,437	12,815	7,428	744,821
45–49	227,525	168,515	127,283	69,797	54,391	17,073	12,302	6,543	683,539
50–54	215,107	160,647	121,798	63,711	53,246	16,338	11,817	5,513	648,237
55–59	168,272	122,587	93,692	46,062	41,110	12,818	7,906	3,418	495,911
60–64	140,535	102,654	74,133	37,870	34,124	10,988	5,594	2,111	408,042
65–69	121,568	89,321	60,179	31,244	29,788	9,248	4,265	1,290	346,923
70–74	118,705	86,795	57,118	28,484	30,325	8,740	3,731	918	334,826
75–79	103,805	75,974	48,959	23,787	27,745	7,819	3,320	588	292,000
80–84	72,230	51,628	34,293	16,288	19,239	5,547	2,159	412	201,800
85+	64,220	48,296	30,155	15,998	17,672	4,899	1,765	307	183,313
Total	3,311,014	2,438,431	1,822,506	949,603	764,466	239,325	161,742	94,293	9,782,588

Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).

Table D5: Estimated resident female population, states and territories, June 2002

Age group	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Australia
0–4	209,998	149,393	120,635	61,267	44,412	14,878	10,193	8,471	619,365
5–9	219,545	158,360	128,718	65,354	47,919	16,064	10,602	8,240	654,942
10–14	222,365	160,854	130,986	68,209	48,895	16,673	11,090	7,690	666,903
15–19	219,024	160,582	129,704	68,547	50,462	16,639	11,914	7,129	664,072
20–24	215,476	164,600	125,384	65,016	47,029	14,105	13,331	7,456	652,455
25–29	235,186	173,789	129,576	66,068	47,466	13,970	12,776	8,558	687,472
30–34	254,762	195,255	140,697	73,271	53,979	16,314	13,161	9,154	756,676
35–39	248,713	186,794	139,540	73,748	55,450	16,992	12,540	8,060	741,963
40–44	255,317	187,635	143,484	75,781	58,882	18,600	12,938	7,521	760,266
45–49	230,346	171,093	130,107	70,701	54,719	17,258	12,223	6,522	693,084
50–54	215,417	160,557	123,151	64,600	52,781	16,242	11,745	5,655	650,212
55–59	180,476	131,947	102,248	50,183	44,420	13,861	8,727	3,635	535,541
60–64	143,193	105,156	77,891	39,445	34,713	11,236	5,845	2,325	419,844
65–69	123,633	91,020	62,742	32,380	30,288	9,446	4,447	1,366	355,344
70–74	117,855	85,628	57,482	28,694	29,724	8,816	3,725	978	332,914
75–79	104,309	76,984	49,611	24,224	27,842	7,709	3,401	632	294,715
80–84	75,377	54,172	36,110	17,269	20,125	5,744	2,266	422	211,487
85+	67,203	49,844	31,552	16,378	18,279	5,118	1,891	324	190,591
Total	3,338,195	2,463,663	1,859,618	961,135	767,385	239,665	162,815	94,138	9,887,846

Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).

Table D6: Estimated resident female population, states and territories, June 2003

Age group	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Australia
0–4	207,840	148,831	121,115	60,967	43,903	14,922	10,125	8,487	616,337
5–9	217,222	157,203	129,778	64,853	47,351	15,733	10,453	8,065	650,780
10–14	223,122	161,896	134,140	68,675	49,096	16,721	10,871	7,745	672,422
15–19	218,754	161,148	130,588	69,025	50,340	16,689	11,865	7,059	665,547
20–24	219,341	168,347	130,226	66,564	47,970	14,287	13,575	7,271	667,642
25–29	230,834	171,726	129,302	65,248	46,283	13,568	12,654	8,277	677,970
30–34	258,371	196,664	145,100	73,716	53,573	16,393	13,163	9,120	766,190
35–39	244,128	186,431	139,805	73,087	54,536	16,690	12,423	7,840	735,055
40–44	257,199	189,969	147,524	77,038	59,090	18,820	12,884	7,553	770,184
45–49	234,453	173,918	134,218	71,733	55,317	17,568	12,255	6,632	706,208
50–54	216,899	161,952	125,720	65,873	53,002	16,594	11,687	5,716	657,524
55–59	190,744	140,572	110,262	53,925	47,162	14,795	9,351	3,931	570,788
60–64	145,895	106,921	81,802	40,634	35,363	11,599	6,096	2,482	430,831
65–69	126,526	93,245	65,471	33,713	30,977	9,703	4,661	1,426	365,745
70–74	116,043	84,892	57,471	28,824	29,040	8,755	3,725	978	329,740
75–79	105,559	77,630	50,718	24,825	27,852	7,760	3,424	679	298,451
80–84	78,343	57,000	37,770	18,292	21,052	5,963	2,428	446	221,296
85+	69,395	51,015	32,887	16,706	18,913	5,247	1,979	344	196,489
Total	3,360,668	2,489,360	1,903,897	973,698	770,820	241,807	163,619	94,051	9,999,199

Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).

Table D7: Estimated resident female population, by age and location, for the 4-year periods 1996–1999 and 2000–2003

Age group	Major cities		Regional		Remote	
	1996–1999	2000–2003	1996–1999	2000–2003	1996–1999	2000–2003
0–4	1,600,570	1,606,087	824,918	793,326	89,390	84,247
5–9	1,606,581	1,649,313	885,651	884,749	89,223	86,855
10–14	1,596,985	1,658,368	893,325	916,183	77,281	77,343
15–19	1,678,788	1,753,798	775,110	827,419	57,360	59,881
20–24	1,922,307	1,895,396	661,594	640,676	67,481	61,541
25–29	2,055,676	2,010,103	759,837	711,458	84,078	77,061
30–34	1,955,620	2,077,219	822,632	822,289	81,993	81,376
35–39	1,974,730	2,009,408	927,544	897,512	80,042	77,290
40–44	1,849,136	1,987,819	871,176	944,486	66,886	71,866
45–49	1,751,752	1,833,881	791,804	861,567	57,652	61,511
50–54	1,476,475	1,721,713	680,898	802,645	47,727	54,749
55–59	1,118,638	1,353,429	560,272	679,897	35,920	42,397
60–64	953,963	1,056,965	495,444	567,183	27,575	31,422
65–69	912,717	905,959	466,860	483,282	22,551	23,852
70–74	879,096	868,785	423,677	443,404	17,275	18,934
75–79	707,131	783,671	329,975	375,007	12,828	14,232
80–84	486,345	553,842	226,538	260,965	8,692	9,776
85+	417,569	504,233	188,248	232,742	7,990	8,570
Total	24,944,079	26,229,990	11,585,503	12,144,790	931,946	942,901

Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).

Table D8: Estimated resident Indigenous and other Australian female populations for Queensland, Western Australia, South Australia and the Northern Territory, for the 4-year period 2000–2003

Age group	Indigenous	Other Australians
0–4	70,550	869,753
5–9	70,770	929,595
10–14	65,439	950,753
15–19	56,374	960,492
20–24	48,140	928,976
25–29	47,744	978,172
30–34	45,516	1,048,270
35–39	38,926	1,073,692
40–44	31,897	1,096,784
45–49	24,960	1,016,407
50–54	19,193	954,852
55–59	13,097	761,893
60–64	10,072	595,512
65–69	6,860	495,432
70–74	4,634	461,314
75+	6,201	948,850
Total	560,373	14,070,747

Note: Only Queensland, South Australia, Western Australia and the Northern Territory have Indigenous death registration data considered to be of a publishable standard. For the purposes of this publication the Indigenous population used as the denominator in calculating mortality rates is the total of these four jurisdictions only. The other Australian population is the total population of the same jurisdictions minus the Indigenous population.

Source: AIHW Population Database based on estimated resident population data compiled by ABS (data extracted March 2005).

Appendix E: National Cervical Screening Programs contact list

New South Wales

Ms Jayne Ross
Program Manager
NSW Cervical Screening Program
PO Box 533
WENTWORTHVILLE NSW 2145
Phone: +61 2 9845 8046
Fax: +61 2 9845 8047
Email: jayne_ross@wsahs.nsw.gov.au
Home page: www.csp.nsw.gov.au

Western Australia

Ms Nerida Steel
Program Manager
Cervical Cancer Prevention Program
1st Floor, Eastpoint Plaza
233 Adelaide Terrace
PERTH WA 6000
Phone: +61 8 9237 6920
Fax: +61 8 9237 6991
Email: nerida.steel@health.wa.gov.au

Victoria

Dr Heather Mitchell
Medical Director
Victorian Cervical Cytology Registry
Email: hmitchel@vcs.org.au

Dr Rosemary Lester
Dept of Human Services
Level 17, 120 Spencer Street
MELBOURNE Vic 3000
Phone: +61 03 9637 4130
Fax: +61 3 9637 4653
Email: rosemary.lester@dhs.vic.gov.au
Home page: www.dhs.vic.org.au

Tasmania

Ms Gail Raw
Program Manager
Dept of Health & Human Services
GPO Box 125B
HOBART Tas 7001

Mr Paul Chandler
Data Manager
Phone: +61 3 6230 7753
Email: paul.chandler@dchs.tas.gov.au
Home page: www.dchs.tas.gov.au

Queensland

Ms Jennifer Muller
Director
Cancer Screening Services
Queensland Health
PO Box 48
BRISBANE Qld 4001
Phone: +61 7 3234 0905
Fax: +61 7 3235 2629
Email: jennifer_muller@health.qld.gov.au

South Australia

Ms Penny Isofidis
Acting Program Manager
SA Cervical Screening Program
2nd Floor, Norwich Centre
55 King William Road
NORTH ADELAIDE SA 5006
Phone: +61 8 8226 8182
Fax: +61 8 8226 8190
Email: penny.isofidis@health.sa.gov.au

Australian Capital Territory

Ms Helen Sutherland
Program Manager
ACT Health
GPO Box 825
CANBERRA ACT 2601
Phone: +61 2 6205 1540
Fax: +61 2 6205 1394
Email: helen.sutherland@act.gov.au

Mr Peter Couvee
Database Manager/Coordinator
ACT Cervical Cytology Register
ACT Community Health
GPO Box 825
Canberra ACT 2601
Phone: +61 2 6205 1955
Fax: +61 2 6205 5035
Email: peter.couvee@act.gov.au

Northern Territory

Ms Vera McMahon
Program Coordinator
Well Women's Cancer Prevention Program
Territory Health Services
PO Box 40596
CASUARINA NT 0810
Phone: +61 8 8922 6445
Fax: +61 8 8922 5511
Email: vera.mcmahon@nt.gov.au

Mr Guillermo Enciso
Data Manager
Casuarina Health Services Centre
Territory Health Services
PO Box 40596
CASUARINA NT 0810
Phone: +61 8 8922 6441
Fax: +61 8 8922 6447 or 6455
Email: guillermo.enciso@nt.gov.au

Australian Government Department of Health and Ageing

Population Screening Section
Department of Health and Ageing
GPO Box 9848
CANBERRA ACT 2601
Phone: +61 2 6289 8302
Fax: 61 2 6289 4021
Home page: www.cervicalscreen.health.gov.au

Appendix F: NHMRC guidelines for the management of women with screen-detected abnormalities (under review)

This reference sheet is a summary of the NHMRC guidelines (1994) for the management of women with screen-detected abnormalities. It is intended to help medical practitioners take appropriate action on receipt of Pap smear reports.

85

Low-grade epithelial abnormalities		
Pap smear report	Investigation	Management
Non-specific minor squamous cell changes/atyphia		Repeat smear at 12-monthly intervals until it reverts to normal.
Minor changes in endocervical cells/low-grade glandular change	Repeat smear in 6 months using cytobrush and spatula. If low-grade abnormality persists, refer for colposcopy and biopsy if indicated.	If endocervical cell abnormality confirmed, refer to gynaecologist for appropriate treatment.
HPV effect/HPV-associated cell changes	Repeat smear at 6-monthly intervals. If HPV-associated cell changes persist after 12 months, refer for colposcopy.	If HPV confirmed, continue with 6-monthly smears until 2 negative reports are received. Repeat smear annually for 2 years then revert to 2-yearly screening.
Possible CIN 1 ± HPV/possible mild dysplasia	Repeat smear at 6-monthly intervals until 2 successive negative reports are received. If lesion persists for 12 months, refer for colposcopy.	If CIN 1 confirmed, follow either observational or active management program as explained on next page.
CIN 1 ± HPV/mild dysplasia	Refer for colposcopy and biopsy if indicated.	If CIN 1 confirmed, follow either observational or active management program as explained on next page. If higher grade abnormality diagnosed, see below.

High-grade epithelial abnormalities		
Pap smear report	Investigation	Management
CIN 2 ± HPV/moderate dysplasia	Refer for colposcopy and directed biopsy.	If CIN 2 confirmed, treatment by gynaecologist with appropriate expertise is required.
CIN 3 ± HPV/severe dysplasia	Refer for colposcopy and directed biopsy.	If CIN 3 confirmed, treatment by gynaecologist with appropriate expertise is required.
CIN 3 ± HPV with possible invasion; endocervical glandular dysplasia; or adenocarcinoma in situ	Refer to gynaecologist with expertise in colposcopic evaluation of malignancies.	Treatment by gynaecologist with appropriate expertise is required.
Invasive squamous cell carcinoma (SCC) or Adenocarcinoma	Refer to gynaecologist skilled in the management of malignancies, or a specialist unit, for urgent evaluation and management.	Treatment by gynaecologist with appropriate expertise is required.
Inconclusive—abnormal cells highly suggestive but not diagnostic of a high-grade abnormality	Refer for colposcopy and possible biopsy, unless there is an obvious diagnostic difficulty, e.g. epithelial atrophy or infection. In this case, treat the problem and repeat the smear.	If high-grade lesion confirmed, treatment by gynaecologist with appropriate expertise is required.

Management of women with low-grade epithelial abnormalities

A cytological assessment of CIN 1 requires referral for colposcopy and, if indicated, biopsy. There is controversy over the management—**observational** and **active**. Both treatment options should be fully discussed with the woman.

Observational management

If the diagnosis of CIN 1 is confirmed and the woman elects not to be treated, cervical smears should be taken at 6-monthly intervals until the abnormality either regresses or progresses. After 2 negative smears at 6-monthly intervals, smears should be taken at yearly intervals. If two consecutive annual smears are normal, the woman can revert to 2-yearly screening.

Active management

Treatment by an accepted method, either ablative or excisional.

88

Pap smear report	Management
Negative/within normal limits	Repeat smear in 2 years.
Negative/within normal limits and no endocervical cells present	Repeat smear in 2 years.
Negative with inflammation	Repeat smear in 2 years.
<i>Note: Investigate any symptoms that are not readily explained, such as post-coital or intermenstrual bleeding. A negative Pap smear must not be taken as reassurance in these circumstances. Further investigation may involve referral to a gynaecologist.</i>	
Unsatisfactory	Repeat smear in 6–12 weeks, with treatment and where possible correction of any problems beforehand if appropriate.

Post-treatment assessment	After initial post-treatment colposcopic assessment by gynaecologist, repeat smear at 6-monthly intervals for 1 year. Following treatment of a high-grade epithelial abnormality, smears should be repeated yearly thereafter. Following treatment for a low-grade epithelial abnormality, revert to normal 2-yearly screening after 2 consecutive normal smears at yearly intervals.
Special circumstances	
Total hysterectomy for CIN	Annual smears from vaginal vault for 5 years, then revert to 2-yearly smears.
Total hysterectomy for benign causes	No further smears required if previous smears were negative. Baseline smear if reason for hysterectomy and/or previous Pap smear history unknown.
Subtotal hysterectomy for benign causes—cervix present	Continue normal 2-yearly screening.
Abnormality during pregnancy	Refer for colposcopy during 1st trimester to exclude invasive disease. If confirmed high-grade abnormality, repeat colposcopy during mid-trimester to exclude progression. Lesion should be reassessed 8 weeks post-partum.

Glossary

Ablative therapy: the destruction of cells on the surface of the cervix using laser therapy, chemicals or diathermy.

Adenosquamous: a mix of adenocarcinoma and squamous cells in the same sample.

Adenocarcinoma: a cancer formed from the cells of a gland.

Adjuvant: enhancing or administered to enhance the effectiveness of a treatment or substance.

AS rate: age-standardised rate

Atypia: the condition of being irregular.

Basement membrane: the delicate, non-cellular layer on which an epithelium is seated. The epithelium forms the surface portion of the skin and lines hollow organs and all passages of the respiratory, digestive and genito-urinary systems.

Benign: not malignant.

Cancer (malignant neoplasm): a term used to describe one of several diseases which result when the process of cell division, by which tissues normally grow and renew themselves, becomes uncontrolled and leads to the development of malignant cells. These cancer cells multiply in an uncoordinated way, independently of normal growth control mechanisms, to form a tumour. This tumour may expand locally by invasion or systemically by metastasis via the lymphatic or vascular systems. If left untreated, most malignant tumours will eventually result in death.

Cancer death: a death where the underlying cause is indicated as cancer. Persons with cancer who die of other causes are not counted in the death statistics in this publication.

CIN (cervical intraepithelial neoplasia): squamous cell carcinoma of the cervix is mostly preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as cervical intraepithelial neoplasia (CIN) graded as CIN I (mild dysplasia), CIN II (moderate dysplasia) and CIN III (severe dysplasia and carcinoma-in-situ). CIN usually occurs at least a decade before cervical cancer. If CIN remains untreated, some women will develop cervical cancer and others will progress to invasive cervical cancer, despite treatment (AIHW: Jelfs 1995).

Cone biopsy: biopsy in which an inverted cone of tissue is excised, as from the uterine cervix.

Colposcopy: an examination of the lower genital tract with a magnifying instrument called a colposcope. This method of conservative evaluation allows the clinician to more accurately assess the cytologic abnormality by focusing on the areas of greatest cellular abnormality and by sampling them with a punch biopsy to attain diagnosis.

Cryosurgery: the destruction of tissue using extreme cold.

Dysplasia: abnormal cell growth.

Endocervical: the inside of the uterine cervix or the mucous membrane lining of the cervix.

Epidemiology: the quantitative study of the distribution and determinants of health-related states and events in populations, and the application of this study to the control of health problems.

Epithelium: the covering of internal and external surfaces of the body, including the lining of vessels and other small cavities. It consists of cells joined by small amounts of cementing substances. It is classified into types on the basis of the number of layers deep and the shape of the superficial cells.

Exfoliate: to break away or remove.

HGA: high-grade abnormalities as defined for this report include CIN 1/2, CIN 2, CIN 3 or adenocarcinoma in situ.

Histology: the microscopic study of the minute structure and composition of tissues.

Hysterectomy: refers to the surgical procedure whereby all or part of the uterus is removed.

Hysterectomy fractions: the proportion of women who have had their uterus removed by hysterectomy.

HPV: Human papilloma virus.

ICD-10: International Classification of Disease – a coding system used to identify the primary site of the malignancy. This classification is in its tenth revision.

Incidence: see *new cancer case*

Intraepithelial: the area within the layer of cell tissues forming the epidermis of a body cavity. These cells comprise contiguous cells having minimum intercellular substance.

Invasive cancer: a tumour whose cells have a tendency to invade healthy or normal tissues.

LGA: low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV) effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified.

Lymph node: masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and through which lymph filters. These are located throughout the body.

Malignant: abnormal changes consistent with cancer.

Metastasis: the process by which a disease is transferred from one part of the body to another, for example via the lymphatic system or the bloodstream.

Mortality: see *cancer death*.

Neoplasia: the process by which tumours are formed.

New cancer case: a person who has a new cancer diagnosed for the first time. One person may have more than one cancer and therefore may be counted twice in incidence statistics if it is decided that the two cancers are not of the same origin. This decision is based on a series of principles set out in more detail in a publication by Jensen et al. (1991).

Pap smear: a test prepared for the study of exfoliated cells from the cervix (refer to Appendix A).

Post-partum: following childbirth.

Radiation therapy: the treatment of disease with any type of radiation, most commonly with ionising radiation, such as X-rays, beta rays and gamma rays.

Screening: the performance of tests on apparently well people in order to detect a medical condition at an earlier stage than would otherwise be the case.

Sensitivity: the proportion of individuals with the disease whom the screening test labels positive.

Squamous malignancy: cervical cancer can be derived from several cells types. One of these cell types is the squamous cell and most cervical cancers are derived from this cell type.

Stroma: the supporting framework of an organ.

References

- ABS (Australian Bureau of Statistics) 1993. Estimated resident population by age and sex: Australian states and territories, June 1987 to June 1992. ABS Cat. No. 3201.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 1995. National Health Survey: summary of results, Australia. ABS Cat. No. 4364.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 1999. Deaths Australia 1998. Cat. No. 3302.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2000. Causes of death 1999. Cat. No. 3303.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2001. Information paper: outcomes of ABS views on remoteness consultation, Australia 2001. Cat. No. 1244.0.00.001. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2002. Australian demographic statistics, September quarter 2002. Cat. No. 3101.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) & AIHW (Australian Institute of Health and Welfare) 2005. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples, 2005. ABS Cat. No. 4704.0. AIHW Cat. No. IHW 14. Canberra: ABS.
- Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R & Inoue M 2002. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series No. 31. Geneva: World Health Organization. <www3/whi.int/whosis/discussion_papers/discussion_papers.cfm>
- AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries) 2002. Cancer in Australia 1999. AIHW Cat. No. CAN 15. Canberra: AIHW (Cancer Series No. 20).
- AIHW: Jelfs PL 1995. Cervical cancer in Australia. Canberra: AIHW (Cancer Series No. 3).
- DHSH (Commonwealth Department of Human Services and Health) 1994a. Summary of NHMRC guidelines for the management of women with screen-detected abnormalities. Canberra: AGPS.
- DHSH (Commonwealth Department of Human Services and Health) 1994b. Screening to prevent cervical cancer: guidelines for the management of women with screen detected abnormalities. Canberra: AGPS.
- Dobson A, Kuulasmaa K, Eberle E, & Scherer J 1991. Confidence intervals for weighted sums of Poisson parameters. *Statistics in Medicine* 10:457-62.
- Doll R & Smith PG 1982. Comparison between cancer registries: age-standardised rates. In: Waterhouse J, Shanmugaratnam K, Muir C & Powell J (eds). *Cancer incidence in five continents, Volume IV*. Lyons: International Agency for Research on Cancer.
- DPPIE (Department of Primary Industries and Energy) & DHSH (Department of Human Services and Health) 1994. Rural, remote and metropolitan areas classification. 1991 Census edition. Canberra: AGPS.
- Jensen OM, Parkin DM, Machennan R & Muir C (eds) 1991. *Cancer registration: principles and methods*. Lyons: International Agency for Research on Cancer.

Marcus AC & Crane LA 1998. A review of cervical cancer screening intervention research: implications for public health programs and future research. *Preventive Medicine* 27:13-31.

Ostor AG & Mulvany N 1996. The pathology of cervical neoplasia. *Current Opinion in Obstetrics and Gynecology* 8:69-73.

Snider JA & Beauvais JE 1998. Pap smear utilization in Canada: estimates after adjusting the eligible population for hysterectomy status. *Chronic Diseases in Canada* 19(1):19-24.

Related publications

AHMAC (Australian Health Ministers' Advisory Council) 1991. Cervical Cancer Screening Evaluation Committee. Cervical cancer screening in Australia: options for change. Australian Institute of Health, Prevention Program Evaluation Series, No. 2. Canberra: AGPS.

AHMAC (Australian Health Ministers' Advisory Council) & AIHW (Australian Institute of Health and Welfare) 1997. The Aboriginal and Torres Strait Islander health information plan... This time, let's make it happen. AIHW Cat. No. HWI 12. Canberra: AIHW.

AIHW (Australian Institute of Health and Welfare) 1998. Breast and cervical screening in Australia 1996-1997. AIHW Cat. No. CAN 3. Canberra: AIHW (Cancer Series No. 8).

AIHW (Australian Institute of Health and Welfare) 2000. Breast and cervical screening in Australia 1997-1998. AIHW Cat. No. CAN 9. Canberra: AIHW (Cancer Series No. 14).

Bell J & Ward J 1998. Cervical screening: linking practice, policy and research in women's health. *Cancer Forum* 22(1):6-11.

Colditz GA, Hoaglin DC & Berkey CS 1997. Cancer incidence and mortality: the priority of screening frequency and population coverage. *The Milbank Quarterly* 75(2):147-73.

DHSH (Commonwealth Department of Health and Family Services) 1998. Screening for the prevention of cervical cancer. Canberra: AGPS.

d'Espaignet ET, Measey ML, Condon JR, Jelfs P & Dempsey KE 1996. Cancer in the Northern Territory 1987-1993. Darwin: Territory Health Services.

Hennekens CH & Buring J 1987. *Epidemiology in medicine*. Boston: Little, Brown and Company.

Jelfs P 1998. Using cancer registries to evaluate cancer screening programs. *Cancer Forum* 22(1):3-6.

Kavanagh AM & Broom DH 1997. Women's understanding of abnormal cervical smear test results: a qualitative interview study. *British Medical Journal* 314:1388-91.

Mathers C, Penm R, Sanson-Fisher R, Carter R & Campbell E 1998. Health system costs of cancer in Australia 1993-94. Canberra: Australian Institute of Health and Welfare. Health and Welfare Expenditure Series No. 4.

McInroe WA, McLean MR, Jones RW & Mullins PR 1984. The invasive potential of carcinoma in situ of the cervix. *Obstetric Gynaecology* 64:451-8.

Sigurdsson KS, Adalsteinsson S & Ragnarsson J 1991. Trends in cervical and breast cancer in Iceland: a statistical evaluation of trends in incidence and mortality for the period 1955-1989, their relation to screening and prediction to the year 2000. *International Journal of Cancer* 48:523-8.

Towler BP, Irwig LM & Shelley JM 1993. The adequacy of management of women with CIN 2 and CIN 3 Pap smear abnormalities. *Medical Journal of Australia* 159:523-8.

Wain G, Ward J & Towler BP 1995. Gynaecological care of women with abnormal Pap smears: how varied is current practice? *Medical Journal of Australia* 162:348-53.